Xencor, Inc. — Q1 2014 Form 10-Q
Reporting period: Three months ended March 31, 2014; balance-sheet figures compare March 31, 2014 with December 31, 2013. Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies using its XmAb platform. It had no approved products or product-sale revenue.
Financial highlights
| Metric | Q1 2014 | Q1 2013 / comparison |
|---|---|---|
| Collaboration, license and milestone revenue | $2.184 million | $1.345 million |
| Research and development expense | $4.228 million | $4.560 million |
| General and administrative expense | $1.723 million | $0.746 million |
| Operating loss | $3.767 million | $3.961 million |
| Net loss | $3.751 million | $4.612 million |
| Net loss per share, basic and diluted | $0.12 | $63.78 |
| Cash used in operating activities | $4.993 million | Cash provided: $1.646 million |
The per-share comparison is affected by the December 2013 IPO and conversion of preferred shares into common stock; the filing also gives effect to a 1-for-3.1 reverse split for prior share data. Gross margin is not applicable to the reported collaboration-based revenue mix, and no gross-margin figure is presented.
- Liquidity: Cash was $72.536 million at quarter-end, down from $77.975 million at December 31, 2013. Management expected approximately $54 million of cash at year-end and believed existing cash plus certain potential milestone payments would fund operations and capital spending through 2016; these estimates depend on assumptions and milestones are uncertain.
- Balance sheet and debt: Total assets were $82.495 million; total liabilities were $12.430 million, including $8.854 million of deferred revenue. Capital lease obligations were approximately $7,000 current, with no material long-term balance. Convertible notes had been exchanged for preferred stock in 2013, and the preferred stock converted to common stock in connection with the IPO.
- Cash flows: Investing activities used $0.448 million, mainly for intangible assets and equipment. Financing activities provided $0.002 million.
Changes versus prior period
- Revenue increased $0.839 million, primarily from CSL licensing revenue and a $0.5 million Merck clinical milestone; Merck’s Phase 1 trial initiation triggered that payment.
- R&D expense declined $0.332 million. Lower XmAb5871 manufacturing costs and reduced XmAb5574/MOR208 spending more than offset increased XmAb7195 and bispecific-program costs.
- G&A expense rose $0.977 million, reflecting higher compensation and professional fees, including costs associated with operating as a public company.
- Net loss narrowed by $0.861 million, helped by improved revenue and the absence of the prior-year convertible-note interest expense. Operating cash flow nevertheless shifted from a source to a use, in part due to lower deferred revenue and lower accounts payable/accrued expenses.
Outlook, risks and notable items
- Management expected preliminary XmAb5871 Phase 1b/2a rheumatoid arthritis results in the second half of 2014. It planned to file an IND for XmAb7195 and begin a Phase 1a trial in the first half of 2014, with preliminary data expected by year-end. The company aimed to advance a bispecific antibody into development by mid-year 2014.
- Management expected R&D costs to increase as clinical trials expand and G&A costs to rise with public-company, compliance and intellectual-property expenses. The company anticipated continuing operating losses and could not estimate the full cost or timing of product development or profitability.
- Funding depends on cash resources, collaborations and potential milestone payments. The company warned that additional financing may be needed; unavailable or unfavorable financing could require delays, reductions or termination of development programs, or licensing rights on unfavorable terms.
- Key risks include clinical and regulatory failure or delays, adverse events, patient enrollment, dependence on partners and contract manufacturers, competition, intellectual-property disputes, and uncertain collaboration payments. The filing reported mild-to-severe gastrointestinal symptoms in some XmAb5871 Phase 1a subjects, an infusion-related reaction with hypotension in one Phase 1b patient as of December 31, 2013, and detectable immunogenicity in 44% of Phase 1a subjects.
- Revenue was concentrated among four partners in Q1 2014; CSL and Amgen represented approximately 32.5% and 25.6% of reported significant revenue, respectively. Cash balances exceeding federal deposit-insurance limits were approximately $72.0 million.
- Management stated disclosure controls were effective at a reasonable-assurance level. However, a material weakness in internal control over financial reporting related to revenue recognition had been identified in connection with the 2013 Form 10-K; remediation steps included hiring experienced accounting staff and adding procedures. The company cautioned that remediation was not assured. No legal proceedings or off-balance-sheet arrangements were reported.
Important facts for investors to verify
- Progress and results from the XmAb5871 and XmAb7195 trials, and whether stated development timelines were met.
- Cash burn, year-end cash expectations and the assumptions underlying the claimed runway through 2016, including the timing and likelihood of collaboration milestones.
- Whether revenue-recognition control weaknesses were fully remediated and whether subsequent filings report any revisions or material weaknesses.
- Partner concentration, partner program decisions and manufacturing supply or licensing arrangements, particularly for XmAb5871 and XmAb7195.
- Clinical safety and immunogenicity findings, regulatory risks, and the status of potential intellectual-property claims.